CompletedNCT03998176
Bictegravir Combination Treatment for People With HIV and Active Substance Use
About this title
Read the official source — NCT03998176Medication studyAges 19+United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: from 19 years.
- Listed locations
- OmahaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: October 9, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 43
- Sponsor
- University of Nebraska
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 19 Years
- Official registry ID
- NCT03998176
- Official title
Show the full official title
A Phase 4, Single-Arm Study of the Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Patients With Active Illicit Substance Use
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Omaha
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Nebraska, a university.
Did this study involve medication?
Yes. The study involved medication, including Bictegravir/emtricitabine/tenofovir alafenamide.
Who was this study for?
Listed age limits: from 19 years.
